Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer

Federman, N; McDermott, R

Federman, N (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat & Orthoped, A2-410 MDCC,10833 Le Conte Ave, Los Angeles, CA 90095 USA.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019; 12 (10): 931

Abstract

Introduction: Detecting oncogenic drivers across multiple cancers has brought about a shift toward a more targeted therapeutic approach. Neurotrophic ......

Full Text Link